Evidence map›Paper›PMID 24893616›Full record

ArticleBMC cancer2014

FOXP1 and TP63 involvement in the progression of myelodysplastic syndrome with 5q- and additional cytogenetic abnormalities.

Alberto L'Abbate, Crocifissa Lo Cunsolo, Ettore Macrì, Paolo Iuzzolino, Cristina Mecucci, Claudio Doglioni, Michelina Coco, Lucia Anna Muscarella, Simona Salati, Enrico Tagliafico and 6 more

Abstract readCase Reports
In one paragraph

Article in BMC cancer, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Alberto L'Abbate
Crocifissa Lo Cunsolo
Ettore Macrì
Paolo Iuzzolino
Cristina Mecucci
Claudio Doglioni
Michelina Coco
Lucia Anna Muscarella
Simona Salati
Enrico Tagliafico
Carla Minoia
Giacoma De Tullio
Attilio Guarini
Nicoletta Testoni
Claudio Agostinelli
Clelia Tiziana StorlazziDepartment of Biology, University of Bari, Via G,Amendola 165/A, Bari 70126, Italy. cleliatiziana.storlazzi@uniba.it.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe progression of low-risk del(5q) myelodysplastic syndrome to acute myeloid leukemia is increased when associated with mutations of TP53, or with additional chromosomal abnormalities. However, to date the prognostic impact and molecular consequences of these rearrangements were poorly investigated. Single additional alterations to del(5q) by balanced chromosome rearrangements were rarely found in myelodysplasia. In particular, balanced alterations involving TP63 and FOXP1 genes were never reported in the literature. CASE PRESENTATION: Here we report on a 79-year woman with an aggressive form of myelodysplastic syndrome with del(5q), no TP53 mutation, and a novel complex rearrangement of chromosome 3 in bone marrow cells. Our results revealed that the FOXP1 and TP63 genes were both relocated along chromosome 3. Strikingly, immunohistochemistry analysis showed altered protein levels, disclosing that this rearrangement triggered the expression of FOXP1 and TP63 genes. FOXP1 was also found activated in other patients with myelodysplasia and acute myeloid leukemia, showing that it is an important, recurrent event.

conclusionsWe document an apparent role of FOXP1 and TP63, up to now poorly documented, in the progression of MDS in our patient who is lacking mutations in the TP53 tumor suppressor gene normally associated with poor outcome in myelodysplastic syndrome with 5q-. Finally, our results may suggest a possible broader role of FOXP1 in the pathogenesis and progression of myelodysplasia and acute myeloid leukemia.

Indexed as

Disease ProgressionAgedChromosome AberrationsChromosomes, Human, Pair 3Chromosomes, Human, Pair 5FemaleForkhead Transcription FactorsHumansIn Situ Hybridization, FluorescenceMyelodysplastic SyndromesPrognosisRepressor ProteinsTranscription FactorsTranslocation, GeneticTumor Suppressor ProteinsForkhead Transcription FactorsFOXP1 protein, humanRepressor ProteinsTP63 protein, humanTranscription FactorsTumor Suppressor Proteins

Identifiers

PMID24893616
PMCPMC4059025

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.